Twenty Years After iPS Cells, the World's First iPS-Derived Products Win Approval in Japan
Two decades after Shinya Yamanaka's 2006 paper, Japan approved the world's first iPS-derived regenerative medicine products on March 6, 2026: Amchepry for Parkinson's disease and RiHEART for severe heart failure. The trial data, the seven-year clock, and the 55 million yen price.